Cero Therapeutics Files 2024 Annual Report

Ticker: CEROW · Form: 10-K · Filed: Apr 15, 2025 · CIK: 1870404

Sentiment: neutral

Topics: annual-report, biotech, sec-filing

TL;DR

Cero Therapeutics filed its 2024 10-K. Formerly Phoenix Biotech.

AI Summary

Cero Therapeutics Holdings, Inc. filed its annual report for the fiscal year ended December 31, 2024. The company, formerly known as Phoenix Biotech Acquisition Corp. until June 30, 2021, is incorporated in Delaware and headquartered in South San Francisco, California. Cero Therapeutics operates in the biological products sector, specifically focusing on products excluding diagnostics.

Why It Matters

This filing provides a comprehensive overview of Cero Therapeutics' financial performance and business operations for the past fiscal year, offering insights for investors and stakeholders.

Risk Assessment

Risk Level: low — This is a standard annual report filing and does not inherently present new risks.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of Cero Therapeutics Holdings, Inc.?

Cero Therapeutics Holdings, Inc. is engaged in the biological products sector, specifically excluding diagnostic substances, as indicated by its SIC code [2836].

When did Cero Therapeutics Holdings, Inc. change its name from Phoenix Biotech Acquisition Corp.?

The company changed its name from Phoenix Biotech Acquisition Corp. on June 30, 2021.

Where are Cero Therapeutics Holdings, Inc.'s principal executive offices located?

The principal executive offices are located at 201 Haskins Way, Suite 230, South San Francisco, CA 94080.

What is the filing date of this 10-K report?

This 10-K report was filed on April 15, 2025.

For which fiscal year is this annual report filed?

This annual report is filed for the fiscal year ended December 31, 2024.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on April 15, 2025 regarding CERO THERAPEUTICS HOLDINGS, INC. (CEROW).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing